We propose a multidisciplinary research program which will integrate substantial institutional expertise in infectious diseases, retrovirology and herpes viruses, antiviral agents, epidemiology, biostatistics, and numerous clinical resources, focusing on the evaluation of novel antiretroviral therapies in HIV-infected persons. In Project 1 a group of clinical investigators with diverse backgrounds will collectively study new antiviral compounds or novel antiviral combinations. Studies will determine the safety and tolerance of such therapies in small groups of patients who will be intensively studied for in vivo evidence of antiviral effects on HIV and other virus infections (EBV, CMV, hepatitis B) that may be cofactors in AIDS pathogenesis. Patients will include hemophiliacs from a large, well studied cohort, and HIV-infected individuals from other risk groups. The pharmacokinetics of antiviral compounds will be closely monitored, as will the impact of liver disease, common in hemophiliacs, on metabolism of antiviral compounds such as AZT. Projects 2-5 comprise a BASIC RESEARCH COMPONENT and explore aspects of HIV biology relevant to antiviral therapy. In Project 2, antiviral synergy and resistance and the mechanisms underlying these phenomena will be studied in different HIV isolates. Project 3 will examine biologic interactions between EBV, CMV and HIV in vitro, and Project 4 will study the role of CMV in progression of immunodeficiency among HIV-infected hemophiliacs. These related projects will provide important information concerning the role of putative cofactor viruses in AIDS pathogenesis, and their potential importance as targets for antiviral therapy. Project 5 will study the molecular evolution of HIV isolates recovered from sexual partners. This study will provide information concerning the sexual transmission of HIV and forces acting on evolution of the env gene. Project 6 (OUTREACH COMPONENT) will evaluate contact tracing among HIV-infected persons identified in a low prevalence state, important because effective contact tracing will be essential for broad application of antiviral therapy. All of the above projects will be supported by a Clinical Retrovirology Laboratory core with sophisticated virologic and serologic capabilities.

Project Start
1987-09-30
Project End
1992-08-31
Budget Start
1988-09-01
Budget End
1989-08-31
Support Year
2
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9
Thio, Chloe L; Smeaton, Laura; Hollabaugh, Kimberly et al. (2015) Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks. AIDS 29:1173-82
Smith, Kimberly Y; Tierney, Camlin; Mollan, Katie et al. (2014) Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis 58:555-63
Kempen, John H; Sugar, Elizabeth A; Varma, Rohit et al. (2014) Risk of cataract among subjects with acquired immune deficiency syndrome free of ocular opportunistic infections. Ophthalmology 121:2317-24
Kozak, Igor; Vaidya, Vijay; Van Natta, Mark L et al. (2014) The prevalence and incidence of epiretinal membranes in eyes with inactive extramacular CMV retinitis. Invest Ophthalmol Vis Sci 55:4304-12
Venuto, Charles S; Mollan, Katie; Ma, Qing et al. (2014) Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. J Antimicrob Chemother 69:3300-10

Showing the most recent 10 out of 174 publications